Cambridge Uni spin-out raises ￡1.8 million for drug development

摘要

PharmEnable, a drug discovery company using advanced medicinal chemistry and Al-enabled approaches to design the next generation of highly complex and specific drug candidate molecules, has closed a ￡1.8 million seed financing round to support its transition into a drug development company. The 2016 spin-out from Cambridge University aims to develop new treatments for conditions with significant unmet clinical need by designing highly complex molecules to address challenging biological targets.